🔬 Non-Invasive Biomarkers: Moving Beyond Routine LFTs
A normal Liver Function Test (LFT) is often met with reassurance in primary care settings. However, when it comes to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), relying solely on routine blood work can create a dangerous, false sense of security.
As clinicians, we must address a challenging diagnostic reality: a significant percentage of patients with progressive fatty liver, and even advanced hepatic fibrosis, present with completely normal ALT and AST levels. Because these enzymes often fluctuate or remain within standard reference ranges during silent tissue remodelling, looking closer using non-invasive tools is essential.
Here is how we can upgrade our primary care triaging using accessible, cost-effective screening pathways:
🛑 The Limitation of Standard LFTs
Transaminases are markers of acute hepatocyte injury, not architectural structural damage. In chronic conditions like MASLD, low-grade, persistent inflammation can drive fibrogenesis without triggering a massive spike in ALT or AST. If we wait for liver enzymes to become elevated before investigating, we risk missing the window where early fibrosis can be actively managed or reversed.
📊 Primary Triaging: Accessible Scoring Systems
Rather than relying on isolated enzyme panels, international clinical guidelines recommend incorporating validated, non-invasive scoring systems directly into standard patient risk stratification. These tools are free, utilize routine lab parameters, and can be calculated in seconds during a standard consultation:
• The FIB-4 Index: A highly reliable primary screening calculator that utilizes a patient's age, AST, ALT, and platelet count. It is exceptionally effective at ruling out advanced fibrosis with a high negative predictive value.
• The NAFLD/MASLD Fibrosis Score (NFS): Another robust tool utilizing clinical variables—including age, BMI, impaired fasting glucose/diabetes, AST/ALT ratio, platelets, and albumin—to help identify patients at elevated risk for advanced structural changes.
🔄 When to Escalate: Advanced Evaluation
Non-invasive biomarkers act as excellent gatekeepers. Based on the calculated scores, patient management follows a clear, logical risk-stratified pathway:
1. Low Risk (FIB-4 less than 1.3): High diagnostic certainty that advanced fibrosis is absent. These patients can be managed conservatively in primary care with metabolic optimization and lifestyle modifications.
2. Indeterminate Risk (FIB-4 1.3 – 2.67): The diagnostic Gray zone. These patients require secondary triaging to clarify their status.
3. High Risk (FIB-4 more than 2.67): High probability of advanced fibrosis. These individuals should be promptly escalated for a FibroScan (transient elastography) to precisely measure hepatic stiffness and controlled attenuation parameter (CAP) or referred directly to a gastroenterologist for specialized evaluation.
🩺 Professional Perspective
Moving from reactive testing to proactive, algorithmic screening allows us to catch progressive liver disease long before structural damage becomes irreversible. By embedding simple tools like the FIB-4 index into our routine metabolic and diabetic check-ups, we can significantly close the diagnostic gap in asymptomatic liver disease.
